ARKG vs XLV
ARK Genomic Revolution ETF vs Health Care Select Sector SPDR Fund
- • XLV has the lower expense ratio at 0.08% vs 0.75% for ARKG.
- • XLV pays a higher dividend yield (1.60%).
Side-by-side metrics
| Metric | ARKG | XLV |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.08% |
Dividend yield Trailing 12-month yield. | 0.00% | 1.60% |
AUM Assets under management — bigger funds are typically more liquid. | $1.73B | $40.60B |
YTD return | 44.53% | 5.74% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.38 | 0.51 |
P/E ratio | — | 29.18 |
Last price | $43.00 | $162.17 |
Inception | — | — |
Issuer | ARK | State Street |
ARKG top holdings
| TWST | Twist Bioscience Corp | 9.15% |
| TEM | Tempus AI Inc Class A common stock | 7.64% |
| ABSI | Absci Corp | 7.01% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 7.00% |
| CRSP | CRISPR Therapeutics AG | 6.56% |
| PSNL | Personalis Inc | 6.19% |
| BEAM | Beam Therapeutics Inc | 4.34% |
| GH | Guardant Health Inc | 4.28% |
| NTRA | Natera Inc | 4.11% |
| ILMN | Illumina Inc | 3.98% |
XLV top holdings
| LLY | Eli Lilly and Co | 16.48% |
| JNJ | Johnson & Johnson | 10.62% |
| ABBV | AbbVie Inc | 7.72% |
| UNH | UnitedHealth Group Inc | 6.56% |
| MRK | Merck & Co Inc | 5.51% |
| AMGN | Amgen Inc | 3.40% |
| TMO | Thermo Fisher Scientific Inc | 3.24% |
| ABT | Abbott Laboratories | 2.75% |
| GILD | Gilead Sciences Inc | 2.73% |
| ISRG | Intuitive Surgical Inc | 2.45% |
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About XLV
XLV (Health Care Select Sector SPDR Fund) is S&P 500 health care sector. Managed by State Street, the fund carries $40.6B in assets under management, an expense ratio of 0.08%, a dividend yield of 1.60%. Its largest holding is Eli Lilly and Co (LLY), which represents 16.5% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.